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physicians and 55% for residents physicians. Similarly the accuracy was higher in
the ambulatory setting than for inpatient, 89% vs. 62%. The yield for the HTN group
was also higher with attendings than residents, 100% vs. 67%, and the yield was
higher in ambulatory versus inpatient settings, 87% vs. 64%. CONCLUSIONS: CDS
based onmedication orders during CPOEmay improve problem lists. The accuracy
and yield of diagnostic information is sensitive to medication type, clinical venue
and possibly clinician type. Mandatory indication based prescribing may not pro-
duce very accurate indication data. There is a substantial need for further research
in this area.
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OBJECTIVES: Treatment strategies for atrial fibrillation (AF) are classified into rate
control and rhythm control. They can be employed through the use of pharmaco-
logical and non-pharmacological approaches. This study described the trend in the
utilization of treatment strategies for the management of AF in newly diagnosed
patients between 1999 and 2008.METHODS: The study was a retrospective cohort
study of administrative claims data from a large nationally dispersed group of
commercially insured subjects from 1999-2008. Newly diagnosed AF patients aged
18 years and with at least one claim for an AF related intervention within 12
months of diagnosis were identified. Based on initial treatment received, patients
were classified in pharmacotherapy or non-pharmacotherapy treatment groups.
Patients initiated on drug-therapies were classified into rate-control (beta-blocker,
calcium channel blocker or digoxin) or rhythm control groups. Descriptive analysis
was conducted to compare the patient demographic characteristics across the
treatment groups. OLS regressionwas conducted to assess linear trends. RESULTS:
Of the 6284 newly diagnosed AF patients who received treatment within one-year,
83.7% underwent pharmacotherapy as the 1st line therapy. Majority (86.3%) of pa-
tients who initiated drug therapy received rate-control medications only. Relative
distribution of different treatments across timedid not vary significantly. However,
within rate-control group, beta-blockers use increased significantly (p 0.0001)
from 47.5% (1999) to 70.58% (2008), whereas use of calcium channel blockers and
digoxin decreased. Non-pharmacotherapy was employed more commonly in the
mid-west (44.95%, p0.0002), in patients younger than 65 years (58.35%, p0.0001)
and its use decreased with increasing age. Males were more likely to undergo
non-pharmacotherapy (69.9%, p 0.0001). CONCLUSIONS: Higher utilization of
rate control as 1st line therapy compared to other treatment strategies is consistent
with the current literature. Greater use of non-pharmacotherapy in younger pa-
tients can be partially explained by the higher success rate in this population.
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BACKGROUND: In the current statin landscape, a need has emerged for simple and
less data-intensive tools to identify patients at risk for cardiovascular events and to
appropriately identify patients for higher-efficacy statin use. OBJECTIVES: To ex-
amine the feasibility of a pharmacy-based algorithm as amarker of cardiovascular
risk to guide appropriate statin selection at the point of service. METHODS: A
retrospective analysis using an integrated database of over 70 pooled health plans
was conducted for the period 2003 to mid-2010. Patients on at least one cardiovas-
cular medication of interest (N 4,276,418) and18 years old werematched by age
and gender to control subjects (not on cardiovascular medications [N 3,046,021]).
Cardiovascular medications included were antihypertensive, antidiabetic, anti-
anginal, antiarrhythmic, anticoagulant, non-statin lipid modifier, and antiplatelet
drugs. Subjects’ cardiovascular risk status (high/moderate/low) was assessed ac-
cording to the current National Cholesterol Education Program guidelines, from
records of diagnoses and procedures. Relative risks were calculated for the likeli-
hood of being at increased risk (high or moderate risk status) as the ratio of pro-
portions of patients on cardiovascular medication versus controls who were at
increased risk. RESULTS: The study population had amean age of 53 years. Overall,
a patient receiving any cardiovascularmedicationwas 2.4 timesmore likely to be at
increased risk (95%CI 2.39,2.40) and was 2.7 times more likely to experience a car-
diovascular event (95%CI 2.73,2.74) than a subject not receiving any cardiovascular
medication. Additionally, it was observed that 27% of the total patients in the
health plans who were on cardiovascular medications accounted for 71.5% of all
cardiovascular events in that group. CONCLUSIONS: A pharmacy algorithm based
on usage of various cardiovascular medications can be used to identify increased
cardiovascular risk. These initial findings demonstrate the potential of using
widely available cardiovascular prescription data in designing statin formulary
management strategies.
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OBJECTIVES: Electronicmedical records (EMRs) increasingly are being used by out-
comes researchers to study the quality of medical care. The study assessed the
impact of non-medical switches in ARB therapy on blood pressure (BP) andmedical
resource utilization including office visits and other antihypertensivemedications.
METHODS: A retrospective study was conducted using the GE Centricity EMR of a
primary care physicians group. Hypertensive patients18 years, continuously en-
rolled, and receiving ARB therapy were included. Switch must have occurred after
the patient was on the first ARB for at least 60 days. The control group remained on
the sameARBanddid not switch. A 1:1matchingwas done on the duration of initial
ARB therapy and presence of diabetes or renal impairment. Demographic charac-
teristics, clinical parameters, ARB use, and office visits were identified. Data was
extracted using Microsoft SQL and statistical analyses were conducted using SPSS
version 18.0. RESULTS: A total of 4,851 patients (mean age 68.23 years, female
58.1%) were prescribed an ARB between 2004 and 2008 out of which 3,083 (63.6%)
stayed on one ARB and 1,768 (36.4%) switched from one ARB to another. Matched
pairs of switchers (n357) and control group (n357) were then identified. There
was no difference in mean baseline systolic BP (SBP) for switchers (143.7921.22)
and control (144.2022.16) but switchers had higher post-switch SBP
(141.0618.52) than control (137.9720.58) (p0.035). More switchers lost control
from index to first visit post-index period (11.5%) than control (8.7%). More antihy-
pertensive agents were added in switchers (1.911.7) than control (1.021.2) in the
post-index period (p0.001). CONCLUSIONS: EMRs have the potential to bridge
research with clinical care by providing real-world data. This study demonstrates
that non-medical switches may result in loss of BP control and additional medical
resource use. Thus, careful consideration should be given before switching thera-
pies for non-medical reasons.
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OBJECTIVES: The study objective was to determine medical resource utilization
and direct and indirect costs following hospitalization with chronic heart failure
(HF). METHODS: Patients with 1 hospitalization with a chronic HF claim (ICD-9
428.22, 428.32 or 428.42) were identified in a US commercial insurance claims da-
tabase from 2004-2008. Patients were observed from beginning of first hospitaliza-
tion (index hospitalization) for chronic HF until disenrollment or end of data avail-
ability. Inpatient, outpatient, and prescription drug data were used to estimate per
patient per month (PPPM) utilization rates. Costs (2009 USD) were calculated per
hospitalization and PPPM for patients65 years, and included insurers’ reimburse-
ment, patient out-of-pocket and sick leave costs. RESULTS: There were 7,814 pa-
tients (mean age 73.2 years, 55.7% male) meeting inclusion criteria. Mean HF hos-
pitalization length of stay increased from 6.7 days at index hospitalization to 8.2
days at fourth re-hospitalization. Rate of HF-related re-hospitalization remained
over 0.045 PPPM throughout 24 months of follow-up, accounting for over 78% of
all-cause hospitalizations. Rate of all-cause and HF-related outpatient visits
peaked at 4.0 and 0.59 visits PPPM, respectively, within the three months after
index hospitalization. Index hospitalization was most expensive (direct medical
costs$31,998). Patient out-of-pocket costs accounted for less than 10% of direct
hospitalization costs and sick leave costs were less than $1,800 at any hospitaliza-
tion. During the study period, outpatient cardiovascular drugs accounted for a
small proportion of total pharmacy costs (approximately 20%); average PPPM cost
varied from $88 to $124, representing less than 1% of the average cost of a HF-
related hospitalization. CONCLUSIONS: Treating chronic HF patients is resource
intensive. The greatest utilization and cost burden occur within the three months
after index hospitalization and patients continue to be burdened after hospitaliza-
tion by high inpatient and outpatient visit rates.
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OBJECTIVES: 1) To determine costs and utilization incurred by employees follow-
ing enrollment in an employer-sponsoredmedication therapymanagement (MTM)
program and 2) to assess the impact of attrition on health care expenditures.
METHODS: A longitudinal study using medical claims. Study participants were
Lucas County employees with diabetes, hypertension and/or hyperlipidemia par-
ticipating in an employer-sponsored open-enrollment MTM program. Claims for
office, emergency roomand inpatient visitswere analyzed for the period of January
2005-July 2010. Disease-related expenditures were tracked for a period of two-year
pre- and post enrollment. All expenditures were calculated as average costs per-
patient pre and post joining and also as total expenditure borne by the employer.
Dropouts were identified from an appointment database. Expenditures were cal-
culated using claims for one year before and after the dropout date. RESULTS:
Claims were received for 361 employees that enrolled in the MTM program. Office
visit expenses went down by $71,442.29 or by 22.36% after joining the MTM pro-
gram. An increase in spending for emergency room visits by $12,597.16 was ob-
served, there were no recurring post-enrollment visits and those that occurred
were for indications that could have increased long-term spending for the em-
ployer. Total expenditure on inpatient visits went up by approximately $7600 but
the amount spent on each visit went down from $7,746.36  4,169.13 to 4,408.07 
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